cisplatin + ifosfamide

Cisplatin + ifosfamide is a combination chemotherapy regimen consisting of two cytotoxic agents, cisplatin and ifosfamide. Both are small molecule alkylating agents used primarily in the treatment of various solid tumors. Cisplatin forms DNA crosslinks, leading to apoptosis by interfering with DNA replication and transcription. Ifosfamide is an oxazaphosphorine alkylating agent that also induces DNA crosslinking and strand breakage, resulting in cell death. This combination has been studied as a treatment for metastatic triple negative breast cancer previously treated with anthracyclines and taxanes, as well as for germ cell tumors (GCT) resistant to prior cisplatin-containing regimens[1][5]. The regimen is typically administered intravenously over several days per cycle, often with mesna uroprotection to prevent hemorrhagic cystitis from ifosfamide[5]. Dose-limiting toxicities include nephrotoxicity (cisplatin), neurotoxicity (ifosfamide), myelosuppression, and other organ toxicities.

Brand names

PlatinolIfex

Other names

CDDP + ifosfamidecis-diamminedichloroplatinum(II) + ifosfamidecisplatin-ifosfamide combinationplatinum-based alkylating agent combination